99mTc-Tc-sestamibi SPECT/CT 诊断肾脏肿瘤:多中心可行性研究(MULTI-MIBI 研究)
该前瞻性多中心诊断试验评估了 MIBI SPECT/CT 用于 cT1(2-7 cm)肾脏肿物术前鉴别良恶性的可行性。2022年12月至2024年2月共筛选109例,50例入组并完成扫描(45.8%,95%CI 36.2-55.7%),来自6个中心。MIBI SPECT/CT 检测恶性肿瘤的敏感度为97.0%(95%CI 84.2-99.9%),特异度为53.8%(95%CI 25.1-80.8%)。作者认为招募可行,初步结果提示可能减少良性肿瘤手术,但受小样本可行性研究限制,需更大规模确定性研究后方可用于实践。
要点
- 6个中心共50例cT1肾肿物患者完成MIBI SPECT/CT,招募率45.8%(95%CI 36.2-55.7%)。
- MIBI SPECT/CT检测恶性肿瘤敏感度97.0%(95%CI 84.2-99.9%),特异度53.8%(95%CI 25.1-80.8%)。
- 所有扫描图像质量均可满足判读,采集与报告无需显著额外培训。
核心结论
- MULTI-MIBI研究显示针对cT1肾肿物的诊断评估研究招募可行。
- 初步诊断准确度估计提示MIBI SPECT/CT可能减少良性肿瘤患者接受手术的数量,同时不遗漏大量恶性肿瘤患者。
- 上述结果受这项可行性研究样本量小的限制,在临床采用前需要更大规模的确定性研究。
研究设计与样本
- 前瞻性、多中心诊断试验评估研究,评估MIBI SPECT/CT对cT1肾肿瘤的诊断价值。
- 连续纳入2022年12月至2024年2月在参与中心就诊的新诊断临床T1(cT1)肾肿物(2-7 cm)成人患者,于组织病理学诊断前接受MIBI SPECT/CT。
- 邀请接受和拒绝参与的患者及参与研究活动的临床医生参加半结构化访谈。
- 主要终点为多中心招募可行性;次要终点包括参与障碍与促进因素的定性评估、用于为确定性研究提供把握度的MIBI SPECT/CT检出癌症的准确度估计、评分者间一致性以及确定扫描采集与判读的培训需求。
主要发现
- 109例被接触患者中,50例入组并接受研究扫描(45.8%,95%CI 36.2-55.7%),来自6个中心。
- MIBI SPECT/CT扫描的采集与报告无需显著额外培训,所有扫描图像质量均足以判读。
- MIBI SPECT/CT检测癌症的敏感度为97.0%(95%CI 84.2-99.9%),特异度为53.8%(95%CI 25.1-80.8%)。
临床怎么用
- 作者认为,初步诊断准确度估计提示MIBI SPECT/CT可能减少良性肿瘤患者接受手术的数量,同时不遗漏大量恶性肿瘤患者。
- 作者指出这些结果受该可行性研究样本量小的限制,在临床采用前需要更大规模的确定性研究。
局限性
- 这些结果受这项可行性研究样本量小的限制。
- 在临床采用前需要更大规模的确定性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: [99mTc]Tc-sestamibi SPECT/CT (MIBI SPECT/CT) is a promising tool to differentiate benign and malignant renal tumours. We tested feasibility of recruitment to a prospective, multi-centre diagnostic test evaluation study of MIBI SPECT/CT for T1 renal tumours. METHODS: Consecutive adult patients with a newly-diagnosed clinical T1 (cT1) renal mass (2-7 cm) presenting to participating sites December 2022 - February 2024 were recruited and underwent MIBI SPECT/CT prior to histopathological diagnosis. Patients who accepted and declined participation and clinicians involved in study activities were invited to a semi-structured interview. The primary endpoint was feasibility of multi-centre recruitment. Secondary endpoints included qualitative assessment of barriers and facilitators to participation, estimates of MIBI SPECT/CT accuracy to detect cancer in order to power a definitive study, inter-rater agreement and identifying training needs for scan acquisition and interpretation. RESULTS: Of 109 approached patients, 50 enrolled and underwent the study scan (45.8%, 95% CI 36.2-55.7%) across 6 sites. MIBI SPECT/CT scans were acquired and reported without the need for significant additional training. All scans were of adequate quality for interpretation. Sensitivity and specificity of MIBI SPECT/CT to detect cancer were 97.0% (95% CI 84.2-99.9%) and 53.8% (25.1-80.8%), respectively. CONCLUSION: MULTI-MIBI has demonstrated feasibility of recruitment to a diagnostic evaluation study for T1 renal masses. Preliminary estimates of diagnostic accuracy suggest that MIBI SPECT/CT could reduce the number of patients with benign tumours undergoing surgery without missing a significant number of patients with malignant disease, however these results are limited by the small sample size in this feasibility study and a larger definitive study is needed prior to adoption in practice.
引用
- Warren H, Wagner T, El-Sheikh S, et al. [99mTc]Tc-sestamibi SPECT/CT for the diagnosis of kidney tumours: a multi-centre feasibility study (MULTI-MIBI Study). Eur J Nucl Med Mol Imaging. 2025. PMID: 40986089. doi:10.1007/s00259-025-07525-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。